Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Item

http://www.wikidata.org/entity/Q35215038

Q35215038

about

Androgen deprivation therapy as backbone therapy in the management of prostate cancer Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies.Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects.Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients Does degree of androgen suppression matter in hormone-sensitive prostate cancer?Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.Hormone levels following surgical and medical castration: defining optimal androgen suppression.Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients What does the research say about androgen use and cerebrovascular events?

P2860

Q28071795-D143E9FD-C301-48EF-9981-9216409022B3 Q29994552-5999A548-8891-4F29-88C5-FB24E660ED2D Q33803812-F201968D-D770-4932-A8E4-B43B62F43EA2 Q36009462-ECAEDC81-7F2F-4A67-96C7-DA3D93A7BD91 Q36970812-69313A78-DC0F-4B0F-96D4-EE1CF83D52A7 Q37214500-26A17F6F-DA2F-4466-BAC1-0030356040B9 Q37672477-3BD8B6C8-7591-4F3D-8231-DE867188E8F9 Q38570555-47AC257E-211F-44C9-A5A3-07AEDF631B0C Q38739542-C519D327-D879-44F0-8DE2-89EDF2885E91 Q39003600-FF41CE62-C1CC-4F4B-AE5C-BBD996A88300 Q39908629-C797EC08-8A17-40C6-A371-318AA4BCB7F3 Q41764150-B3353FB7-B4B3-4845-8142-89CDD16A7461 Q42654761-7D73D7AB-32E9-47B5-8DD2-626A4EC5A1D5 Q42750245-AD672905-C126-4089-B573-955B701EF4CA Q47610526-B40888AC-33D8-4C35-9837-CA9568C2C8AC Q49466230-95AE8FA5-49C3-4A35-B936-C2C553615EEC Q49787745-5D289011-670E-4BEE-839A-653B4336263F Q50092875-D3A1DDFE-17F3-40E9-94EA-D9CDBE01023A Q50125356-7E76FF3A-3E74-4B72-86F3-DA0651B38FF8 Q52572665-1DEF0D88-7A55-451F-A4EE-8C464EB1A871 Q52647565-7D326534-9FF5-4E90-88E1-370752A90963 Q53762958-DA53ECAC-E6CF-498E-80B6-BCA930B8B92A Q53798282-A9277E3F-4ADF-4770-B276-17AB530E688F Q55157282-C7A52CCD-EEFA-4312-A2EB-F6F91F8C1AD1 Q57150670-4A694727-F024-48B1-B89F-13AC654C3F84 Q58574549-EF8F4860-0B9D-45D0-A74F-53F6EFE7F209

P2860

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Item

http://www.wikidata.org/entity/Q35215038

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu